Background-Ischemic preconditioning (PC) represents a state-of-the-art technique for myocardial preservation. Although certain intracellular mediators have been shown to play a role in PC, the exact nature of the trigger for PC is not known.
M ammalian hearts have a remarkable ability to adapt themselves to potentially lethal exogenous stresses, which include environmental stresses such as hypoxia, heat shock, and oxidative stress. [1] [2] [3] Increased tolerance to a sustained ischemic insult by hearts previously exposed to cyclic episodes of brief periods of ischemia and reperfusion has been documented in numerous experimental models. This transient adaptive response associated with decreased reperfusion-induced arrhythmias, increased recovery of postischemic contractile function, and reduced infarct size is known as ischemic preconditioning (PC). 4 Despite the existence of an astronomic number of papers in the literature demonstrating the cardioprotective abilities of PC, the underlying cytoprotective mechanisms remain elu-sive. The current hypothesis suggests that the trigger for classic PC is one or more intracellular mediators including catecholamines, adenosine, nitric oxide, bradykinin, and angiotensin. 5, 6 These intracellular mediators are released into the coronary circulation within minutes of ischemia. 7, 8 These mediators either alone or in combination potentiate a cascade of signal transduction involving multiple kinases leading to the induction of the expression of genes. 9, 10 A large number of studies including our own have implicated a role for bradykinin in PC. 6, 11 We have also demonstrated the cardioprotective abilities of ACE inhibitors. 12 The present study reinforces the hypothesis that ACE inhibition potentiates PC through bradykinin B 2 -receptor activation. Isolated rat hearts were perfused in the absence or presence of losartan (an angiotensin AT 1 inhibitor), HOE 140 (a bradykinin B 2 blocker) or both losartan and HOE 140 together. The results document that HOE 140 increased myocardial ischemia/reperfusion injury by blocking the bradykinin B 2 receptor and increasing angiotensin II formation. This suggests a role of the bradykinin B 2 receptor in PC. Losartan reduced ischemia-reperfusion injury by modulating the amount of bradykinin release from the heart. The infarct size-lowering ability of losartan was partially blocked and the antiapoptotic role was completely blocked by HOE 140, documenting both the bradykinin-dependent and bradykinin-independent mechanisms of losartan.
Methods

Isolated Perfused Heart Preparation
Sprague-Dawley rats weighing Ϸ300 g were anesthetized with pentobarbital (80 mg/kg IP). After intravenous administration of heparin (500 IU/kg), the chests were opened and the hearts were rapidly excised and mounted on a nonrecirculating Langendorff perfusion apparatus. 1 The perfusion buffer used in this study consisted of a modified Krebs-Henseleit bicarbonate buffer (KHB) (in mmol/L: 118 NaCl, 4.7 KCl, 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 25 NaHCO 3 , 10 glucose, and 1.7 CaCl 2 , gassed with 95% O 2 -5% CO 2 , filtered through a 5-m filter to remove any particulate contaminants, pH 7.4) that was maintained at a constant temperature of 37°C and was gassed continuously for the entire duration of the experiment. Left atrial cannulation was then carried out, and, after allowing for a stabilization period of 10 minutes in the retrograde perfusion mode, the circuit was switched to the antegrade working mode, which allows for the measurement of myocardial contractility as well as aortic and coronary flows, as described in detail in a previous report. 1 Essentially, it is a left heart preparation in which the heart is perfused at a constant preload of 17 cm H 2 O (being maintained by means of a Masterflex variable speed modular pump, Cole Palmer Instrument Co) against an afterload of 100 cm H 2 O.
At the end of 10 minutes, after the attainment of a steady-state cardiac function, baseline functional parameters were recorded and coronary effluent samples were collected for biochemical assays. The circuit was then switched back to the retrograde mode and hearts were perfused (nϭ6 per group) with either KHB alone (control) or KHB supplemented with losartan (4.5 mol/L), HOE 140 (10 mol/L), or both for 15 minutes. At the end of this period, hearts were subjected to global ischemia for 30 minutes followed by 2 hours of reperfusion. The first 10 minutes of reperfusion was in the retrograde mode to allow for postischemic stabilization and thereafter in the antegrade working heart mode to allow for assessment of functional parameters. A schematic of the protocol is shown in Figure 1 . Myocardial infarct size and apoptosis were determined in the heart, whereas creatine kinase, bradykinin, and angiotensin release were estimated in the coronary effluent as described below.
Measurement of Ventricular Function
Aortic pressure was measured with a Gould P23XL pressure transducer (Gould Instrument Systems Inc) connected to a side arm of the aortic cannula. The signal was amplified with a Gould 6600 series signal conditioner and monitored on a CORDAT II real-time data acquisition and analysis system (Triton Technologies). Heart rate, developed pressure (defined as the difference of the maximum systolic and diastolic aortic pressures), and the first derivative of developed pressure were all derived or calculated from the continuously obtained pressure signal. Aortic flow was measured with a calibrated flowmeter (Gilmont Instruments Inc), and coronary flow was measured by timed collection of the coronary effluent dripping from the heart.
Evaluation of Myocardial Infarct Size
Hearts to be used for infarct size calculations were taken on termination of the experiment and immersed in 1% triphenyl tetrazolium solution in phosphate buffer (Na 2 HPO 4 88 mmol/L, NaH 2 PO 4 1.8 mmol/L) for 10 minutes at 37°C and then stored at Ϫ70°C for later processing. Frozen hearts (including only ventricular tissue) were sliced transversely in a plane perpendicular to the apical-basal axis into Ϸ0.5-mm-thick sections, blotted dry, placed in between microscope slides, and scanned on a Hewlett-Packard Scanjet 5p single-pass flat bed scanner. With the use of NIH 1.61 image processing software, each digitized image was subjected to equivalent degrees of background subtraction, brightness, and contrast enhancement for improved clarity and distinctness. Risk (equivalent to total left ventricular muscle mass) as well as infarct zones of each slice were traced, and the respective areas were calculated in terms of pixels. The weight of each slice was then recorded to facilitate the expression of total and infarct masses of each slice in grams. The risk and infarct volumes (in cm 3 ) of each slice were then calculated on the basis of slice weight to remove the introduction of any errors caused by nonuniformity of heart slice thickness. The risk volumes and infarct volumes of each slice were summed to obtain the risk and infarct volumes for the whole heart. Infarct size was taken to be the percent infarct volume/risk volume for any one heart.
Evaluation of Apoptosis
Immunohistochemical detection of apoptotic cells was carried out with the use of TUNEL, in which residues of digoxigenin-labeled dUTP are catalytically incorporated into the DNA by terminal deoxynucleotidyl transferase II, an enzyme that catalyzes a templateindependent addition of nucleotide triphosphate to the 3Ј-OH ends of double-or single-stranded DNA. 13 The incorporated nucleotide was incubated with a sheep polyclonal antidigoxigenin antibody followed by a FITC-conjugated rabbit anti-sheep IgG as a secondary antibody as described by the manufacturer (Apop Tag Plus, Oncor Inc). The sections (nϭ3) were washed in PBS 3 times, blocked with normal rabbit serum, and incubated with mouse monoclonal antibody recognizing cardiac myosin heavy chain (Biogenesis Ltd) followed by staining with TRIRC-conjugated rabbit anti-mouse IgG (200:1 dilution, Dako Japan). The fluorescence staining was viewed with a confocal laser microscope (Olympus Co). The number of apoptotic cells was counted and expressed as a percentage of total myocyte population.
Figure 1.
Schemata of experimental protocol. Isolated perfused rat hearts were stabilized for 15 minutes followed by 30-minute ischemia (30ЈIsch) and 2-hour perfusion. Ventricular function (VF) and RIA for bradykinin and angiotensin II were performed at baseline (BL) and during reperfusion. Coronary effluents were taken at baseline and at 30 (R30), 60 (R60) and 120 (R120) minutes of reperfusion. Myocardial infarct size and apoptosis were evaluated at end of 120 minutes of reperfusion.
Sato et al Preconditioning With Losartan
III-347
Measurements of Bradykinin and Angiotensin in Coronary Effluent
Bradykinin and angiotensin II were assayed by radioimmunoassay (RIA) with standard RIA kits obtained from Peninsula Laboratories Inc.
Statistical Analysis
A 2-way analysis of ANOVA followed by Scheffé's test was first carried out with the Primer Computer Program (McGraw-Hill, 1988) to test for differences between groups. If differences were established, the values were compared by means of a Student's t test for paired data. The values were expressed as meanϮSEM. The results were considered significant at a value of PϽ0.05.
Results
Effects of Losartan and HOE 140 on Postischemic Ventricular Function
There were no differences in baseline function between the control and treatment groups. As expected, on reperfusion, the absolute values of aortic flow, developed pressure, and dP/dt max were decreased in all groups as compared with the baseline values, whereas coronary flow did not show a significant change (Figures 2 and 3 ). Losartan-treated rat hearts displayed significant recovery of postischemic myocardial function. This was evidenced by significantly higher pressure and aortic flow readings throughout the reperfusion period. Significant differences were observed at all time points. In contrast, HOE 140 -treated hearts displayed significantly lower postischemic recovery in aortic flow, developed pressure, and dP/dt max compared with those for the control group. HOE 140 when combined with losartan significantly attenuated the losartan-mediated improved ventricular func-tion. Heart rates varied from 282 to 302 bpm for all groups and did not vary between groups (results not shown).
Effects of Losartan and HOE 140 on Myocardial Infarction
Thirty minutes of ischemia followed by 2 hours of reperfusion (control) caused a large myocardial infarct (Ͼ30% area of risk) ( Figure 4 ). Normalized infarct size in percent (infarct size/area of risk) in the control heart was 34.2Ϯ2.0 versus 20.0Ϯ1.8 for losartan, 41.3Ϯ3.2 for HOE 140, and 25.4Ϯ1.9 for losartanϩHOE 140 -treated hearts. Thus, losartan reduced whereas HOE 140 increased infarct size significantly compared with control. The change in infarct size by losartan was significantly increased by HOE 140. 
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Effects of Losartan and HOE 140 on Cardiomyocyte Apoptosis
We performed double-antibody staining by using antibody in an Apop Tag kit and the monoclonal antibody recognizing cardiac myosin heavy chain to specifically identify cardiomyocyte apoptosis. A significant number of apoptotic myocytes as well as nonmyocyte cells were visible in the normal hearts subjected to 30 minutes of ischemia and 2 hours of reperfusion ( Figure 5A ). The number of apoptotic cells expressed as a percentage of total cardiomyocyte population ( Figure 5B ) was higher in the hearts that were pretreated with HOE 140 compared with control hearts. In contrast, only a few apoptotic cells and almost no apoptotic cardiomyocytes were visible in the losartan-treated hearts. This antiapoptotic property of losartan was completely abolished by HOE 140 because the number of apoptotic cells increased significantly (as in the HOE 140 -treated group) when hearts were simultaneously treated with losartan and HOE 140.
Effects of Losartan and HOE 140 on Release of Bradykinin and Angiotensin
As expected, an increased amount of bradykinin and angiotensin II was found in the coronary effluent from the postischemic control myocardium ( Figure 6 ). HOE 140 almost completely blocked the release of bradykinin but dramatically increased the angiotensin II content of the effluent. Losartan blocked angiotensin II and dramatically increased bradykinin generation. Combined treatment of the hearts with HOE 140 and losartan reduced both bradykinin and angiotensin II content in the perfusate.
Discussion
The results of our study indicated significant postischemic ventricular recovery with losartan, an AT 1 receptor blocker, as demonstrated by improved developed pressure and aortic flow and reduced myocardial infarct size. In contrast, HOE 140 aggravated ischemia-reperfusion injury by reducing the recovery of postischemic contractile function and increasing myocardial infarct size. Additionally, cardiomyocyte apoptosis was reduced with losartan whereas HOE 140 accelerated apoptotic cell death. Ischemia/reperfusion induced the generation of angiotensin II and bradykinin. HOE 140 blocked bradykinin release and augmented the formation of angiotensin II whereas losartan blocked the formation of angiotensin II and augmented bradykinin formation. The results document that losartan reduced whereas HOE 140 increased myocardial ischemia/reperfusion injury by blocking AT 1 and bradykinin B 2 receptors, respectively, suggesting a role of the bradykinin B 2 receptor in PC. Losartan provided cardioprotection in 2 ways: (1) by reducing infarct size and improving ventricular function and (2) by inhibiting cardiomyocyte apoptosis. The antiapoptotic function of losartan was completely blocked and the infarct size-lowering ability was partially blocked by HOE 140, suggesting a bradykinindependent and bradykinin-independent function of losartan. This is schematically illustrated in Figure 7 , in which blockage of the AT 1 receptor by losartan prevented angiotensin II formation, whereas blockage of the B 2 receptor with HOE 140 both limited bradykinin release and increased angiotensin II formation. Both bradykinin and angiotensin have been implicated in PC. 6, 11 In the pig heart, the bradykinin level was found to increase within 3 minutes of PC and was blocked by HOE 140. 14 Perfusion of guinea pig hearts with bradykinin for 10 minutes protected the hearts against free radical injury. 15 The cardioprotection induced by bradykinin in both the pig and guinea pig was reversed by HOE 140, thus suggesting the role of the bradykinin B 2 receptor in such preservation. 14, 16 In a study with open-chest dogs, the antiarrhythmic effects of PC were abolished by blockade of the bradykinin B 2 receptor. 17 Similar to bradykinin, ACE inhibitors were found to potentiate a preconditioning effect on the myocardium. For example, enalaprilat, an ACE inhibitor, and an angiotensin II receptor antagonist, EXP 3174, reduced infarct size and augmented the PC effect in the pig heart. 18 Another ACE inhibitor, captopril, also potentiated the myocardial infarct size-limiting effect of PC. 19 In the present study, losartan was used to block the AT 1 receptor. There are at least 2 distinct subtypes of angiotensin II receptors, designated as AT 1 and AT 2 receptors. 20 The best characterized receptor antagonists for AT 1 and AT 2 are losartan and PD123319 (1-{[4-(dimethylamino)-3methylphenyl]methyl}-5-(diphenylacetyl)-4,5,6,7tetrahydro-1H-imidazo [4,5-c] pyridine-6-carboxylic acid), respectively. 20 Although both the AT 1 and AT 2 receptors are known to modulate cardiac function, the AT 1 receptors particularly affect the contractile and mitogenic action of angiotensin II. 21 The activation of the AT 1 receptor enhances phospholipase C, resulting in the formation of inositol triphosphate (IP 3 ) and leading to intracellular Ca 2ϩ overloading. 22 Thus, blockade of the AT 1 receptor makes losartan an excellent antihypertensive drug for treatment of hypertension. In addition, losartan has found its use in the treatment of stroke, malignant nephrosclerosis, and myocardial infarction.
Although ACE antagonism or AT 1 receptor blockade has been found to mimic preconditioning, the mechanism(s) of action remains unclear. It has been reported that ACE inhibitors function in part by preserving bradykinin, and captopril, in particular, was found to potentiate the infarct size-limiting effect of PC through the bradykinin B 2 receptor in an isolated rabbit heart model. 23 Another recent study showed similar results as reported here, namely the bradykinin-dependent cardioprotective effects of losartan against ischemia and reperfusion in rat hearts. 24 In the present study, both the postischemic ventricular recovery and infarct size-lowering abilities of losartan were partially inhibited by HOE. Interestingly enough, the losartan-mediated reduction of cardiomyocyte apoptosis was completely abolished by HOE 140.
Our own laboratory has supported the notion that cardiomyocyte apoptosis and necrosis are independent contributors to myocardial infarction, and ischemia and reperfusion lead both to apoptotic cell death and cell necrosis whereas PC results in the decrease in both apoptosis and necrosis. 25 The results of this study also demonstrated increased apoptosis in the ischemic reperfused myocardium, with losartan significantly decreasing apoptotic cell death. This was completely reversed by HOE 140, suggesting that the losartan-mediated decrease in cardiomyocyte apoptosis was due to bradykinin B 2 receptor activation. These results were further supported by the observation that losartan significantly increased bradykinin formation that was blocked by HOE 140.
In conclusion, this study showed that losartan mimicked the preconditioning effects by its ability to reduce infarct size and to improve postischemic ventricular recovery. These cardioprotective properties of losartan were only partially blocked by HOE 140. In contrast, losartan-mediated decrease in cardiomyocyte apoptosis was completely inhibited by HOE 140, suggesting the apoptotic cell death-lowering ability of losartan was due to the bradykinin B 2 -receptor activation. This study has documented for the first time that losartan provided cardioprotection by both bradykinindependent and bradykinin-independent pathways. 
